^
Association details:
| Biomarker: | DDR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Landscape of DNA damage response gene mutations in microsatellite-stable colorectal carcinoma.
Published date:
05/26/2022
Excerpt:
...we evaluated the molecular roles of DDR pathway and the immune microenvironment in efficacy of immunotherapy in MSS CRC….The clinical data suggested the patient with DDR pathway alteration had longer OS (354.7 ± 134.0 days, PR) than the others with DDR wild type (247.1± 258.4 days, PD/SD) after PD-1-targeted therapies (P = 1.587e-08). Moreover, the patient with DDR pathway alteration showed significant longer PFS (312.3 ± 179.2 days, PR) compared with DDR wild type (163.3 ± 157.7 days, PD/SD) through immune therapies (P = 4.249e-10).
DOI:
10.1200/JCO.2022.40.16_suppl.e15558
Source:
Title:
1640 - Correlations of DNA damage response gene alterations with response to immune checkpoint inhibitors are different in solid tumors
Published date:
03/10/2021
Excerpt:
DDR alterations are associated with ICIs efficacy in melanoma (P = 0.0007), colorectal cancer (P = 0.0012), NSCLC (P = 0.0224), bladder cancer (P = 0.0439), and breast cancer (P = 0.0451).
Source:
Title:
Mutation of DNA damage repair genes confers an immune-privileged tumor microenvironment in colorectal cancer with a prognostic value.
Published date:
05/13/2020
Excerpt:
Our data suggest that DDR mutation is a potential prognostic biomarker for ICI-treated CRCs.
DOI:
10.1200/JCO.2020.38.15_suppl.4080
